Skip to main content
. 2002 Jul 16;99(16):10641–10646. doi: 10.1073/pnas.162360499

Fig 1.

Fig 1.

Biochemical and functional characterization of CD21 SCR1–SCR2. (A) SDS/PAGE showing purified glycosylated (gl) and deglycosylated (dg) protein. The expressed fragment has glycosylation sites at Asn-101 and Asn-107. (B) EBV binding (block) to CD21-expressing B cells (Top) can be inhibited by glycosylated (gl-CD21, second from Top) or deglycosylated (dg-CD21, third from Top) CD21 SCR1–SCR2, but not by glycosylated CD46 SCR1–SCR4 (gI-CD46, Bottom), a closely related protein that does not bind EBV (see Methods).